InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,576.98
(
0.07%
)
US TECH 100
19,916.80
(
0.12%
)
Dow Jones
39,291.97
(
-0.13%
)
Brent Oil
84.72
(
-0.81%
)
Bitcoin
57,866.43
(
2.05%
)
Post# of 252535
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 831
Posts 120003
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: NP1986 post# 129465

Monday, 12/05/2011 9:12:58 AM

Monday, December 05, 2011 9:12:58 AM

Post# of 252535
GILD’s PK-booster, Cobicistat shows non-inferiority to ritonavir when added to Reyataz + Truvada:

http://finance.yahoo.com/news/Gilead-Boosting-Agent-bw-2115580062.html?x=0

GILD plans to submit an NDA for standalone Cobicistat in 2Q12, and BMY licensed its use as a booster for Reyataz to be used in place of ritonavir (#msg-68350662). The more consequential use of Cobicistat, however, is as a constituent of GILD’s ‘Quad’ combination pill for HIV, which consists of Elvitegravir, Cobicistat, and Truvada.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up